NASDAQ:NVUS

Novus Therapeutics Provides Update on OP0201

Monday, January 13, 2020 - 11:30am

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the ongoing phase 2a study C-006 in acute otitis media patients.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the ongoing phase 2a study C-006 in acute otitis media patients.
  • The company plans to close enrollment in the first calendar quarter of 2020 once approximately 100 patients have been enrolled.
  • We look forward to completing the first OP0201 clinical trial in pediatric patients with acute otitis media, said Gregory J. Flesher, Chief Executive Officer.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat.

Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Friday, January 10, 2020 - 10:19pm

The shares of common stock issuable upon exercise of the warrants are registered pursuant to a registration statement on Form S-1 (File No.

Key Points: 
  • The shares of common stock issuable upon exercise of the warrants are registered pursuant to a registration statement on Form S-1 (File No.
  • The gross proceeds to the company from the exercise of the warrants are expected to be approximately $4.7 million, prior to deducting placement agent fees and estimated offering expenses.
  • The company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).

Novus Therapeutics to Participate in Two Investor Conferences

Friday, November 29, 2019 - 1:30pm

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate in two investor conferences in December.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate in two investor conferences in December.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).
  • The Company has two platform technologies, each with the potential to be developed for multiple indications.
  • Novus also has a foam-based drug delivery technology platform (OP01xx), which may be developed in the future to deliver drugs into the ear, nasal, and sinus cavities.

Novus Therapeutics Reports Third Quarter 2019 Financial Results

Wednesday, November 13, 2019 - 12:30pm

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended September 30, 2019.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended September 30, 2019.
  • We expect results from this study to be available in the first half of 2020.
  • Research and development (R&D) expenses were $1.5 million for the three months ended September 30, 2019, compared to $1.7 million for the same period in 2018.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).

Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion

Tuesday, October 29, 2019 - 11:30am

Study C-009 is designed to explore the effect of daily administration of OP0201 in patients with COME, a non-infectious form of otitis media.

Key Points: 
  • Study C-009 is designed to explore the effect of daily administration of OP0201 in patients with COME, a non-infectious form of otitis media.
  • The study will enroll infants and children with three months or longer of bilateral middle ear effusion and hearing loss.
  • The primary endpoints of study C-009 will be the resolution of middle ear effusion and/or restoration of hearing.
  • We are pleased to have alignment with the FDA on our planned Phase 2a chronic otitis media with effusion study, said Dr. Catherine C. Turkel, President of Novus Therapeutics, Inc.

Novus Therapeutics to Participate in Two Upcoming Investor Conferences

Thursday, August 29, 2019 - 1:30pm

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate in two upcoming investor conferences in New York City.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate in two upcoming investor conferences in New York City.
  • Presentation: September 24 at 3:00 PM in St. Germain II (2nd Floor)
    Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).
  • The Company has two platform technologies, each with the potential to be developed for multiple indications.
  • Novus also has a foam-based drug delivery technology platform (OP01xx), which may be developed in the future to deliver drugs into the ear, nasal, and sinus cavities.

Novus Therapeutics Reports Second Quarter 2019 Financial Results

Tuesday, August 13, 2019 - 9:05pm

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended June 30, 2019.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended June 30, 2019.
  • The company had $13.7 million in cash as of June 30, 2019.
  • For the six-months ended June 30, 2019, R&D expenses were $5.3 million, compared to $2.4 million for the same period in 2018.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).

Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media

Monday, June 10, 2019 - 1:30pm

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that data from OP0201 study C-002 will be presented during the 20th International Symposium on Recent Advances in Otitis Media, being held June 9-13, 2019 in Los Angeles, CA.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that data from OP0201 study C-002 will be presented during the 20th International Symposium on Recent Advances in Otitis Media, being held June 9-13, 2019 in Los Angeles, CA.
  • The study was conducted at a single phase 1 unit in the United States.
  • Additional information about study C-002 can be found at clinicaltrials.gov using the identifier NCT03748758 and at novustherapeutics.com .
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).

Novus Therapeutics Reports First Quarter 2019 Financial Results

Tuesday, May 14, 2019 - 9:05pm

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended March 31, 2019.

Key Points: 
  • Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended March 31, 2019.
  • In addition, we completed enrollment of our 14-day safety and tolerability study in healthy adults and expect to report results next month.
  • R&D expenses were $3.0 million during the three-months ended March 31, 2019, compared to $1.1 million for the same period in 2018.
  • G&A expenses were $1.9 million during the three-months ended March 31, 2019, compared to $1.7 million for the same period in 2018.

Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market

Thursday, May 2, 2019 - 9:01pm

Novus also issued unregistered warrants to purchase up to 6,898,224 shares of common stock.

Key Points: 
  • Novus also issued unregistered warrants to purchase up to 6,898,224 shares of common stock.
  • LifeSci Capital LLC acted as financial advisor to the company in connection with the offering.
  • The gross proceeds to Novus, before deducting placement agent fees and other offering expenses, are approximately $10.7 million.
  • Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).